<DOC>
	<DOCNO>NCT00941642</DOCNO>
	<brief_summary>Lovaza fish oil supplement approve FDA . It available prescription treatment hypertriglyceridemia ( &gt; 500 mg/dl ) . The primary mechanism appear reduction hepatic production triglyceride . Also decrease hepatic production low density lipoprotein ( VLDL ) . There also may antioxidant property well . The thought behind use Lovaza treatment non-alcoholic fatty liver disease ( NAFLD ) two fold . It would help decrease production triglyceride liver antioxidant property decrease production free radical liver . In , steatohepatitis , fibrosis , perhaps cirrhosis liver cancer would prevent .</brief_summary>
	<brief_title>Placebo Controlled Study Using Lovaza Treatment Non-Alcoholic Fatty Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Over age 18 Abnormal liver enzymes &gt; 40 IU/L . Definition normal ALT 19 woman 30 man . Patients must meet ATP III criterion metabolic syndrome : Central obesity measure waist circumference . Men great equal 40 inch . Women great equal 35 inch . Blood HDL cholesterol . Men le 40 mg/dL . Women le 50 mg /dL . Blood pressure great equal 130/85 . Fasting glucose great equal 100 mg/dL less 126mg/dL 2 separate occasion . Fasting blood triglyceride great equal 150 mg/dL . Hepatitis B C negative Autoimmune Hepatitis , Wilson 's Disease , Hemochromatosis negative , etc . NASH NAFLD biopsy degree : Below age 18 . Other Causes Liver inflammation . Daily alcohol consumption excess 20 gram / day men 10 gram / day woman . If participant unable quantify his/her alcohol intake , exclude . Taking prescribed medication know cause fatty liver disease 6 month prior enrollment . Also , subject secondary cause fatty liver disease ( ie . Gastric bypass ) exclude study . Cirrhosis . Subjects oral insulinsensitizing agent drug currently use treatment NAFLD . Such agent include fibrates , Vitamin E , Sadenosylmethionine , betaine , Nacetylcysteine , milk thistle extract . Diabetes ( fast sugar 126mg/dl ) . Pregnancy lactation . Women child bear potential must negative serum pregnancy test screening , negative urine pregnancy test prior treatment practice acceptable form barrier contraception duration study . Any serious chronic disease opinion Principal Investigator ( PI ) , may affect assessment safety efficacy parameter . This include limited , patient malignancy , Basal Cell Carcinomas . Patients , opinion site PI , suitable candidate enrollment would comply requirement study . Patients liver transplant . Any allergy fish .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Nonalcoholic Fatty Liver Disease ( NAFLD )</keyword>
	<keyword>Lovaza</keyword>
	<keyword>Steatosis</keyword>
	<keyword>Non-Alcoholic steatohepatitis ( NASH )</keyword>
</DOC>